Comparative Pharmacology
Head-to-head clinical analysis: PROPOXYPHENE HYDROCHLORIDE W ASPIRIN AND CAFFEINE versus VIVLODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROPOXYPHENE HYDROCHLORIDE W ASPIRIN AND CAFFEINE versus VIVLODEX.
PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE vs VIVLODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a centrally acting opioid analgesic that binds to mu-opioid receptors. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. Caffeine is a CNS stimulant that may enhance analgesia.
COX-2 inhibitor; reduces prostaglandin synthesis via inhibition of cyclooxygenase-2 (COX-2) with minimal COX-1 inhibition.
1-2 capsules orally every 4-6 hours as needed; maximum 6 capsules per day. Each capsule contains propoxyphene hydrochloride 65 mg, aspirin 325 mg, and caffeine 32.4 mg.
Once daily oral administration of 100 mg or 200 mg capsules. The recommended dose is 100 mg once daily; dose may be increased to 200 mg once daily if response is inadequate. Maximum daily dose: 200 mg.
None Documented
None Documented
Propoxyphene: 6-12 hours (up to 36 hours in overdose); norpropoxyphene: 30-36 hours. Aspirin: 2-3 hours for low doses, up to 15-30 hours in overdose. Caffeine: 3-6 hours; prolonged in liver disease.
Terminal elimination half-life of the active moiety meloxicam is approximately 20 hours (range 12-24 h), allowing once-daily dosing in chronic pain.
Renal elimination of propoxyphene and its metabolites (mainly norpropoxyphene) accounts for approximately 70-90% of the dose; fecal excretion is minimal (<10%). Aspirin is renally eliminated as salicylates (75-90% as conjugates, 10% free), while caffeine is primarily metabolized and its metabolites are excreted renally.
VIVLODEX is a meloxicam NSAID prodrug. Following hydrolysis to meloxicam, excretion is primarily hepatic (metabolism) and renal (urine). Approximately 50% of meloxicam dose is excreted in urine as metabolites and <5% as parent drug; about 40% in feces. Biliary excretion is minor.
Category D/X
Category C
NSAID / Antiplatelet
NSAID